AbbVie screens as cheaper, but Johnson & Johnson’s diversification is the counterweight in 2026 buy-theory debate

A new 2026 stock-picking comparison from Yahoo Finance set up a contrast between AbbVie and Johnson & Johnson, focusing less on day-to-day fundamentals and more on how investors weigh valuation against resilience.

The piece argues that AbbVie can look more attractive on price, noting that the shares trade at a lower valuation level than Johnson & Johnson. It frames that affordability as part of the “cheaper” appeal for investors looking for value in healthcare.

At the same time, the analysis cautions that AbbVie’s earnings base is heavily concentrated, meaning a larger portion of results depends on a smaller set of revenue sources than investors may prefer if conditions change. In the article’s framing, that concentration increases sensitivity to setbacks affecting key products or indications.

By comparison, the Yahoo Finance write-up characterizes Johnson & Johnson as benefiting from a “fortress” balance sheet and a wider healthcare portfolio. In other words, the argument for JNJ rests on durability and diversification rather than a low price tag.

The debate reflects a broader pattern in healthcare investing in which the same category can produce very different risk profiles. Companies with multiple engines often face more internal variability, but they can be easier to underwrite if one area weakens. Companies with fewer major drivers can be rewarding when momentum is strong, but investors typically scrutinize downside scenarios more closely.

Still, the comparison in the Yahoo Finance post appears primarily to be an investor-logic exercise rather than a document loaded with new disclosures. The article’s themes emphasize relative valuation, portfolio breadth, and financial resilience, but it does not, in the information available here, provide specific figures, segment-level revenue tables, or updated guidance that would let readers independently verify the magnitude of the risks.

One key caveat for readers is that the Yahoo Finance framing, as described, does not spell out which revenue streams drive AbbVie’s concentration, how diversified Johnson & Johnson’s portfolio is on a quantified basis, or what exact balance-sheet metrics support the “fortress” characterization. Without those details, the discussion is better understood as a checklist of factors than as a fully evidenced, numbers-forward valuation model.

Looking ahead, investors comparing these two names would likely focus on what changes in the next earnings cycles, including whether AbbVie’s revenue concentration risk is rising or stabilizing, and whether Johnson & Johnson’s balance-sheet strength and portfolio mix translate into consistent operating results. The next reports and any updates on product performance would be the clearest reality check for the thesis laid out in the comparison.